Bays, Harold E.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial

Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,829

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 1,444

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., et al. (2023) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 988

Multicenter, placebo-controlled trial of lorcaserin for weight management.

Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 911

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 807

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2

Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 784

Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach

Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism

Peroxisome Proliferator-Activated ReceptorsAdipokines, Inflammation, and Metabolic Diseases

Cited by 664

Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association

Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Disease and Adiposity

Cited by 521

The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys: Relation of BMI to diabetes mellitus

Bays, H. E., Chapman, R. H., Grandy, S., & the SHIELD Investigators’ Group (2007) · International Journal of Clinical Practice

Diabetes, Cardiovascular Risks, and LipoproteinsObesity, Physical Activity, Diet

Cited by 510

Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes

Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 501

PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes

Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 493

Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis

Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., et al. (2024) · New England Journal of Medicine

Osteoarthritis Treatment and MechanismsPharmacology and Obesity Treatment

Cited by 440

Adiposopathy

Bays, H. E. (2011) · Journal of the American College of Cardiology

Cardiovascular Disease and AdiposityAdipokines, Inflammation, and Metabolic Diseases

Cited by 431

Anti-PCSK9 Monotherapy for Hypercholesterolemia

Koren, M. J., Lundqvist, P., Bolognese, M., Neutel, J. M., Monsalvo, M. L., Yang, J., Kim, J. B., Scott, R., Wasserman, S. M., & Bays, H. (2014) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 411

Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study

Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics

Lipoproteins and Cardiovascular HealthFatty Acid Research and Health

Cited by 385

Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation

Lopez-Jimenez, F., Almahmeed, W., Bays, H., Cuevas, A., Di Angelantonio, E., le Roux, C. W., Sattar, N., Sun, M. C., Wittert, G., Pinto, F. J., et al. (2022) · European Journal of Preventive Cardiology

Cardiovascular Disease and AdiposityDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 362

Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)

Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 358

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy

Ballantyne, C. M., Laufs, U., Ray, K. K., Leiter, L. A., Bays, H. E., Goldberg, A. C., Stroes, E. S., MacDougall, D., Zhao, X., & Catapano, A. L. (2020) · European Journal of Preventive Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 358

Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)

Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 342

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Pieber, T. R., Bode, B., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Wallenstein, S. O. R., Buse, J. B., Akın, S., Aladağ, N., et al. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 287

Ten things to know about ten cardiovascular disease risk factors

Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology

Cardiovascular Health and Risk FactorsHealth Promotion and Cardiovascular Prevention

Cited by 274

Safety considerations with niacin therapy

Guyton, J. R., & Bays, H. E. (2007) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthFolate and B Vitamins Research

Cited by 269

Statin Safety: An Overview and Assessment of the Data—2005

Bays, H. (2006) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 264

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study

Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 243